An expanded access record providing Triheptanoin in Long Chain Fatty Acid Oxidation Disorders, sponsored by Ultragenyx Pharmaceutical Inc. Available. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Ultragenyx Pharmaceutical Inc · Expanded access
Expanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.
Long Chain Fatty Acid Oxidation Disorders (LC-FAOD) and other Non-FAOD conditions, where applicable: Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies.
For full details, please visit the links provided below.
26 studies on the registry are indexed under VLCAD deficiency; 6 are open to participants now.
Browse VLCAD deficiency studies →Ultragenyx Pharmaceutical Inc is the lead sponsor of 63 studies on the registry; 8 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
- The participant must not be eligible for a UX007 clinical trial
Liquid for oral (PO) or enteral tube administration
Also known as: UX007
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ultragenyx Pharmaceutical Inc →